May 12, 2021

New Research:

Appearance in the Colorectal Disease Peer-Reviewed Medical Journal

We are excited to announce our appearance in the Colorectal Disease peer reviewed medical journal of two article abstracts, one is entitled ‘eXroid Electrotherapy: a low-risk treatment for all grades of internal haemorrhoids’.

In this article we outline how the eXroid electrotherapy treatment successfully treats all 4 grades of haemorrhoids (1-4). Our article also importantly demonstrates, that while haemorrhoids cause significant morbidity and place a significant burden on the NHS, eXroid is an attractive out-patient based treatment option, with a very low risk of complications compared to other treatments.

The research follows 812 patients, including 503 men, 309 women with a median age of 54yrs, who were aged between 18 and 96. These individuals were treated between March 2019 and November 2020, and our article discusses how they reacted to the eXroid treatment.

Key conclusions of our research are:

– eXroid electrotherapy can be used successfully in all four grades of internal haemorrhoid disease.

– eXroid electrotherapy can be used in those patients taking anticoagulants without the need to stop these prior to treatment

– The risk of serious adverse events for the eXroid procedure is very low.

We're here to help you

eXroid®: fully regulated and accredited

Our service has been evaluated by the National Institute for Health and Care Excellence (NICE) who have produced two sets of approval guidelines which accredit the treatment as safe and effective (IPG525 and MIB201). eXroid is a registered and regulated service Provider with the Care Quality Commission (CQC) as we strive for the highest levels of care and service standards.

The eXroid service is also PCI DSS compliant, giving both financial assurance and security to our patients when they make their payments with us.